| 16.37 -0.1 (-0.61%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.14 | 1-year : | 23.53 |
| Resists | First : | 17.25 | Second : | 20.14 |
| Pivot price | 15.84  |
|||
| Supports | First : | 14.99 | Second : | 13.6 |
| MAs | MA(5) : | 16.12 |
MA(20) : | 15.45 |
| MA(100) : | 14.85 |
MA(250) : | 15.44 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 64.6 |
D(3) : | 62.2 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 20.89 | Low : | 12.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMRN ] has closed below upper band by 21.7%. Bollinger Bands are 1.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.8 - 16.89 | 16.89 - 16.95 |
| Low: | 16.03 - 16.12 | 16.12 - 16.19 |
| Close: | 16.23 - 16.38 | 16.38 - 16.49 |
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Tue, 30 Jun 2026
AMARIN (AMRN) CEO Berg exercises RSUs as ADSs, 3,197 shares withheld for tax - Stock Titan
Tue, 30 Jun 2026
Amarin says VASCEPA remains a first-line option as triglyceride drugs expand - Stock Titan
Fri, 26 Jun 2026
Price to sales forward of Amarin Corporation plc – NASDAQ:AMRN - TradingView
Thu, 25 Jun 2026
Amarin (AMRN) Stock Forum and Discussion - Moomoo
Fri, 12 Jun 2026
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Thu, 04 Jun 2026
Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 37.8 (%) |
| Held by Institutions | 22.9 (%) |
| Shares Short | 613 (K) |
| Shares Short P.Month | 620 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.42 |
| Profit Margin | -15.6 % |
| Operating Margin | -17.8 % |
| Return on Assets (ttm) | -0.5 % |
| Return on Equity (ttm) | -7.3 % |
| Qtrly Rev. Growth | 7.4 % |
| Gross Profit (p.s.) | 5.41 |
| Sales Per Share | 10.33 |
| EBITDA (p.s.) | -0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -10.24 |
| PEG Ratio | 0.8 |
| Price to Book value | 0.76 |
| Price to Sales | 1.58 |
| Price to Cash Flow | 13.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|